point-counterpoint: active surveillance for intermediate-risk prostate cancer - con
Published 10 months ago • 1.4K plays • Length 9:59Download video MP4
Download video MP3
Similar videos
-
9:15
point-counterpoint: active surveillance for intermediate-risk prostate cancer - pro
-
11:13
active surveillance in favorable intermediate-risk prostate cancer
-
17:45
point-counterpoint: oncotype dx genomic prostate score in active surveillance – canary pass study
-
16:11
point-counterpoint q&a w/ dr. lin: oncotype dx genomic prostate score in active surveillance
-
8:07
point-counterpoint q&a w/ dr. klein: oncotype dx genomic prostate score in active surveillance
-
12:19
active surveillance 2022: who qualifies, who does not and how should it be monitored
-
1:42
active surveillance or intervention in intermediate-risk prostate cancer
-
1:47
dr. loblaw on using active surveillance to monitor men with intermediate-risk prostate cancer
-
11:36
point-counterpoint: will conventional imaging become obsolete? – con
-
20:23
active surveillance criteria and follow-up protocol
-
18:14
active surveillance: intermediate disease and high-volume grade group 1 prostate cancer
-
23:37
active surveillance who is the right patient and what is the right protocol
-
20:50
active surveillance 2021 - from bench to bedside
-
1:58
integrated diagnostics and patient selection for active surveillance and treatment
-
18:53
focal therapy for men with intermediate risk prostate cancer
-
20:39
active surveillance or: shrinking the gray zone
-
25:24
active surveillance in 2021 part 2: imaging and biomarkers
-
24:42
a radiation oncologist's approach to active surveillance and our role in local therapy
-
40:52
global grand rounds: active surveillance for prostate cancer with matthew e. nielsen, md, ms, facs